1
|
Cutuli B, Lemanski C, De Lafontan B, Chauvet MP, De Lara CT, Mege A, Fric D, Richard-Molard M, Mazouni C, Cuvier C, Carre A, Kirova Y. Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients. Clin Breast Cancer 2020; 20:e164-e172. [DOI: 10.1016/j.clbc.2019.08.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2019] [Revised: 08/04/2019] [Accepted: 08/06/2019] [Indexed: 12/27/2022]
|
2
|
Sanati S. Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. THE AMERICAN JOURNAL OF PATHOLOGY 2019; 189:946-955. [DOI: 10.1016/j.ajpath.2018.07.031] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Revised: 07/05/2018] [Accepted: 07/13/2018] [Indexed: 12/12/2022]
|
3
|
Wachter DL, Wachter PW, Fasching PA, Beckmann MW, Hack CC, Riener MO, Hartmann A, Strehl JD. Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. Arch Pathol Lab Med 2018; 143:206-211. [DOI: 10.5858/arpa.2017-0578-oa] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Context.—
Paget disease of the breast, in most cases, represents intraepidermal spread of ductal carcinoma in situ. Molecular subtypes of invasive carcinoma of the breast have prognostic and therapeutic significance and show characteristic distribution. Little is known about the distribution of molecular subtypes in Paget disease of the breast.
Objectives.—
To examine the distribution of molecular subtypes in Paget disease of the breast and to compare them to concurrent invasive carcinoma of the breast, if present.
Design.—
We examined 48 cases of Paget disease of the breast with immunohistochemistry and antibodies against estrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67, as well as HER2 chromogenic in situ hybridization, to classify the cases into molecular subtypes. Then, we compared the results to the molecular subtypes of associated invasive carcinoma of the breast, if present.
Results.—
The HER2 subtype was the most common found in Paget disease of the breast, followed by the luminal B subtype and 2 cases of the triple-negative subtype. The associated invasive carcinoma cases were most often of the luminal B subtype, followed by the HER2 subtype and the triple-negative subtype. The molecular subtype of Paget disease and invasive carcinoma was congruent in most of the cases.
Conclusions.—
Molecular subtypes of invasive carcinoma of the breast can already be detected in Paget disease. The distribution of molecular subtypes of Paget disease and of Paget disease–associated invasive carcinoma differs from invasive carcinoma without associated Paget disease, with the HER2 subtype overrepresented in Paget disease and associated invasive carcinoma and the luminal and triple-negative subtypes underrepresented.
Collapse
Affiliation(s)
- David L. Wachter
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| | - Peter W. Wachter
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| | - Peter A. Fasching
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| | - Matthias W. Beckmann
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| | - Carolin C. Hack
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| | - Marc-Oliver Riener
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| | - Arndt Hartmann
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| | - Johanna D. Strehl
- From the Institute of Pathology (Drs D. L. Wachter, P. W. Wachter, Hartmann, and Strehl) and the Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg (Drs Fasching, Beckmann, and Hack), University Hospital, Erlangen, Germany; and OptiPath, Joint Practice for Pathology, Frankfurt am Main, Germany (Dr Riener)
| |
Collapse
|
4
|
Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis. Clin Breast Cancer 2018; 18:157-167.e6. [DOI: 10.1016/j.clbc.2017.12.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 12/11/2017] [Indexed: 12/14/2022]
|
5
|
Tanaka K, Hida T, Oya Y, Yoshida T, Shimizu J, Mizuno T, Kuroda H, Sakakura N, Yoshimura K, Horio Y, Sakao Y, Yatabe Y. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Cancer 2017; 123:1731-1740. [PMID: 28177518 DOI: 10.1002/cncr.30539] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 12/06/2016] [Accepted: 12/12/2016] [Indexed: 11/07/2022]
Abstract
BACKGROUND Lung adenocarcinoma in the young is a rare entity, and the oncogenic genetic alterations (GAs) and clinical characteristics associated with this disease are poorly understood. Conversely, it has been demonstrated that young age at diagnosis defines unique biology in other cancers. For this report, the effects of young age on lung adenocarcinoma are reported. METHODS The authors retrospectively screened 1746 consecutive patients who were diagnosed with stage I through IV adenocarcinoma between 2009 and 2015 and identified 81 who were aged 40 years or younger at diagnosis. The clinical and genetic characteristics of this younger population were analyzed. RESULTS Of the 81 younger patients identified, 36 (44%) were men, 36 (44%) were never smokers, and the median age was 36 years (range, 26-40 years). Thirty-three patients (41%) harbored anaplastic lymphoma kinase (ALK) translocations, 24 (30%) had epidermal growth factor receptor (EGFR) mutations, and 2 (2%) had v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. Rare oncogenic GAs also were studied in patients who had wild-type ALK/EGFR/KRAS adenocarcinoma, including 4 patients with HER2 mutations, 2 with Ret proto-oncogene (RET) translocations, and 2 with ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) translocations. Notably, oncogenic GAs (P < .001), ALK (P < .001) and ROS1 (P = .033) translocations, and HER2 mutations (P < .001) were associated with young age, and a similar trend was observed for RET translocations (P = .108). Younger patients who had adenocarcinoma without GAs had a significantly worse prognosis compared with older patients without GAs (overall survival, 8.9 vs 16.4 months; P < .001) and patients with GAs (24.9 months; P < .001). CONCLUSIONS Younger patients with adenocarcinoma have a distinctly unique prevalence of oncogenic GAs. Comprehensive oncogenic GA screening is especially recommended for personalized medicine strategies in this population. Cancer 2017;123:1731-1740. © 2017 American Cancer Society.
Collapse
Affiliation(s)
- Kosuke Tanaka
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Toyoaki Hida
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Yuko Oya
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Tatsuya Yoshida
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Junichi Shimizu
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Tetsuya Mizuno
- Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Hiroaki Kuroda
- Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Noriaki Sakakura
- Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Kenichi Yoshimura
- Department of Biomedical Statistics, Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan
| | - Yoshitsugu Horio
- Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Yukinori Sakao
- Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Yasushi Yatabe
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
| |
Collapse
|
6
|
Wang W, Wang X, Liu J, Gao J, Wang J, Wang X, Zhao D. Breast cancer in young women of Chinese Han population: A retrospective study of patients under 25 years. Pathol Res Pract 2016; 212:1015-1020. [PMID: 27712977 DOI: 10.1016/j.prp.2016.08.010] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 08/29/2016] [Accepted: 08/29/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND Breast cancer has aggressive clinical and pathological features in younger women and is characterized by poorer prognosis than in older women. However, data on women <25 years are limited. OBJECTIVE The aim of the present study was to evaluate the different pathological characteristics and prognostic factors in Chinese women with breast cancer <25 years at the time of diagnosis. METHODS This retrospective study included 94 patients (aged <25) of Chinese Han population with operable breast cancer at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences between January 1, 2000 and September 30, 2015. Univariate and multivariate Cox regression analysis were performed. The median follow-up duration was 64 months (range, 11-200 months). RESULTS The HER2-positive and triple-negative groups had a higher T (P=0.002) and N stage than the luminal A group (P=0.014). The 5-year overall survival (OS) was 90.4%, and the disease-free survival (DFS) was 74.5%. The 5-year DFS varied among the four groups were 94.1 vs. 76.9 vs. 45.5 vs. 66.7%, respectively; P=0.009. Multivariate analysis showed that only estrogen receptor (ER) status was a significant predictor of OS and DFS [Hazard ratio (HR)=5.3, 95% confidence interval (CI)=1.11-25.27, P=0.036; HR=2.712, 95%CI=1.27-5.80, P=0.01). CONCLUSION HER2-positive and triple-negative breast cancer are more likely to have poor prognosis in patients<25years. Hence, ER status may be identified as an independent prognostic factor for predicting young women with breast cancer.
Collapse
Affiliation(s)
- Wenyan Wang
- Breast Surgical Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Xin Wang
- Breast Surgical Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Jiaqi Liu
- Breast Surgical Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Jidong Gao
- Breast Surgical Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Jie Wang
- Breast Surgical Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Xiang Wang
- Breast Surgical Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
| | - Dongbing Zhao
- Abdominal Surgical Oncology Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
| |
Collapse
|
7
|
Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol 2016; 2:313-20. [PMID: 26720421 DOI: 10.1001/jamaoncol.2015.4482] [Citation(s) in RCA: 152] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
IMPORTANCE Non-small-cell lung cancer (NSCLC) diagnosed in young patients is rare, and the genomics and clinical characteristics of this disease are poorly understood. In contrast, the diagnosis of other cancers at a young age has been demonstrated to define unique disease biology. Herein, we report on the association of young age with targetable genomic alterations and prognosis in a cohort of 2237 patients with NSCLC. OBJECTIVE To determine the relationship between young age at diagnosis and the presence of a potentially targetable genomic alteration, disease prognosis, and natural history. DESIGN, SETTING, AND PARTICIPANTS A cohort of all 2237 patients with NSCLC who were genotyped at the Dana-Farber Cancer Institute between January 2002 and December 2014 were identified. Tumor genotype, patient characteristics, and clinical outcomes were collected and studied at a National Cancer Institute-designated comprehensive cancer center. Multivariate logistic regression was used to analyze the relationship between age and mutation status, and multivariate Cox proportional hazard models were fitted for survival analysis. MAIN OUTCOMES AND MEASURES The frequency of targetable genomic alterations by defined age categories as well as the association of these age groups with survival. Age categories used in this analysis were younger than 40, 40 to 49, 50 to 59, 60 to 69, and 70 years or older. RESULTS A cohort of 2237 patients with NSCLC was studied. Of the 2237 participants, 1939 (87%) had histologically confirmed adenocarcinoma, 269 (12%) had NSCLC not otherwise specified, and 29 (1%) had squamous histologic findings; 1396 (63%) had either stage IIIB or IV cancers; and median (range) age was 62 (20-95) years. We found that gene mutations for EGFR (P = .02) and ALK (P < .001) were associated with cancer diagnosis at a younger age, and a similar trend existed for ERBB2 (P = .15) and ROS1 (P = .10) but not BRAF V600E (P = .43). Among patients tested for all 5 targetable genomic alterations (n = 1325), younger age was associated with an increased frequency of a targetable genotype (P < .001). Those diagnosed at 50 years or younger have a 59% increased likelihood of harboring a targetable genotype. While presence of a potentially targetable genomic alteration treated with a targeted agent was associated with improved survival, the youngest and oldest age groups had similarly poor outcomes even when a targetable genotype was present. CONCLUSIONS AND RELEVANCE Younger age is associated with an increased likelihood of harboring a targetable genotype and is an underappreciated clinical biomarker in NSCLC. The survival of young patients with NCSLC is unexpectedly poor compared with other age groups, suggesting more aggressive disease biology. These findings underscore the importance of comprehensive genotyping, including next-generation sequencing, in younger patients with lung cancer.
Collapse
Affiliation(s)
- Adrian G Sacher
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| | - Suzanne E Dahlberg
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts4Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | - Jennifer Heng
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Stacy Mach
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Pasi A Jänne
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts5Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massac
| | - Geoffrey R Oxnard
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts2Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
8
|
Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol 2016; 29:249-58. [PMID: 26769139 PMCID: PMC5484584 DOI: 10.1038/modpathol.2015.158] [Citation(s) in RCA: 109] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 12/07/2015] [Accepted: 12/09/2015] [Indexed: 12/25/2022]
Abstract
The host immune response has a key role in breast cancer progression and response to therapy. However, relative to primary invasive breast cancers, the immune milieu of breast ductal carcinoma in situ (DCIS) is less understood. Here, we profile tumor infiltrating lymphocytes and expression of the immune checkpoint ligand programmed death ligand 1 (PD-L1) in 27 cases of DCIS with known estrogen receptor (ER), progesterone receptor, and human epidermal growth factor 2 (HER-2) expression using tissue microarrays. Twenty-four cases were pure DCIS and three had associated invasive ductal carcinoma. Tumors were stained by immunohistochemistry for PD-L1, as well as the lymphocyte markers CD3, CD4, CD8, FoxP3, and CD20. The expression of PD-L1 by DCIS carcinoma cells and tumor infiltrating lymphocytes was determined, and the average tumor infiltrating lymphocytes per high power field were manually scored. None of the DCIS cells expressed PD-L1, but 81% of DCIS lesions contained PD-L1+ tumor infiltrating lymphocytes. DCIS with moderate-diffuse tumor infiltrating lymphocytes was more likely to have PD-L1+ tumor infiltrating lymphocytes (P=0.004). Tumor infiltrating lymphocytes with high levels of PD-L1 expression (>50% cells) were seen only in triple-negative DCIS (P=0.0008), and PD-L1-tumor infiltrating lymphocytes were seen only in ER+/HER-2-DCIS (P=0.12). The presence of PD-L1+ tumor infiltrating lymphocytes was associated with a younger mean patient age (P=0.01). Further characterization of the DCIS immune microenvironment may identify useful targets for immune-based therapy and breast cancer prevention.
Collapse
Affiliation(s)
- Elizabeth Thompson
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, United States 21287
| | - Janis M. Taube
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, United States 21287,Department of Pathology and Dermatology, The Johns Hopkins Hospital, Baltimore, MD, United States, 21287
| | - Hillary Elwood
- Department of Pathology, University of New Mexico, Albuquerque, NM, United States, 87131
| | - Rajni Sharma
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, United States 21287
| | - Alan Meeker
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, United States 21287
| | | | - Pedram Argani
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, United States 21287,Department of Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, United States, 21287
| | - Ashley Cimino-Mathews
- Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, United States 21287,Department of Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, United States, 21287,Corresponding authors: Ashley Cimino-Mathews, MD, Departments of Pathology and Oncology, Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Weinberg Building 2242, 401 N. Broadway St, Baltimore MD 21287, , Leisha A. Emens, MD PhD, Department of Oncology, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 409, Baltimore, MD 21231-1000,
| | - Leisha A. Emens
- Department of Oncology, Sidney Kimmel Cancer Center, The Johns Hopkins Hospital, Baltimore, MD, United States, 21287,Corresponding authors: Ashley Cimino-Mathews, MD, Departments of Pathology and Oncology, Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Weinberg Building 2242, 401 N. Broadway St, Baltimore MD 21287, , Leisha A. Emens, MD PhD, Department of Oncology, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 409, Baltimore, MD 21231-1000,
| |
Collapse
|
9
|
Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old. Breast 2015; 24:461-7. [DOI: 10.1016/j.breast.2015.04.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2014] [Revised: 02/09/2015] [Accepted: 04/08/2015] [Indexed: 11/21/2022] Open
|
10
|
Perez AA, Balabram D, Rocha RM, da Silva Souza Á, Gobbi H. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast. J Histochem Cytochem 2015; 63:408-16. [PMID: 25711229 DOI: 10.1369/0022155415576540] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2014] [Accepted: 02/10/2015] [Indexed: 12/21/2022] Open
Abstract
We assessed the co-expression of cell cycle-related biomarkers in a series of 121 consecutive cases of high-grade ductal carcinoma in situ (DCIS), pure or associated with invasive carcinoma, and their associations with the different immunoprofiles of DCIS. Cases were identified from the histopathology files of the Breast Pathology Laboratory, Federal University of Minas Gerais, Brazil, from 2003 to 2008. The expression of estrogen receptor, progesterone receptor, HER2 overexpression, cytokeratin 5, epidermal growth factor receptor 1, cyclooxygenase-2, p16 and Ki67 were assessed. Tumors were placed into five subgroups according to their immunohistochemical profile: luminal A, luminal B, HER2, basal-like and "not classified". We found that the basal phenotype was associated with a higher frequency of p16-positive cases (83%) and the luminal A phenotype showed a higher frequency of p16-negative cases (93%; p=0.000). The association of biomarkers p16(+)/Ki67(+)/COX2(+) was expressed in 02/06 cases (33.3%) of the basal phenotype but in only 01/70 cases (1.4%) of the luminal A phenotype (p=0.01). The co-expression of p16(+)/Ki67(+)/COX2(-) was associated with a basal phenotype (p=0.004). P16 expression, p16(+)/Ki67(+)/COX2(+) and p16(+)/Ki67(+)/COX2(-) co-expression showed significant associations with the basal phenotype and these profiles could be used to guide more aggressive treatment strategies in patients with high-grade DCIS.
Collapse
Affiliation(s)
- Amanda Arantes Perez
- Breast Pathology Laboratory, School of Medicine, Federal University of Minas Gerais, Brazil (AAP, DB, ADSS, HG)
| | - Débora Balabram
- Breast Pathology Laboratory, School of Medicine, Federal University of Minas Gerais, Brazil (AAP, DB, ADSS, HG)
| | | | - Átila da Silva Souza
- Breast Pathology Laboratory, School of Medicine, Federal University of Minas Gerais, Brazil (AAP, DB, ADSS, HG)
| | - Helenice Gobbi
- Breast Pathology Laboratory, School of Medicine, Federal University of Minas Gerais, Brazil (AAP, DB, ADSS, HG)
| |
Collapse
|
11
|
Molecular alterations in non–small cell lung carcinomas of the young. Hum Pathol 2014; 45:2379-87. [DOI: 10.1016/j.humpath.2014.08.005] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/22/2014] [Revised: 08/11/2014] [Accepted: 08/13/2014] [Indexed: 01/18/2023]
|